SAN DIEGO, CA, Jul 07 (MARKET WIRE) --
Althea Technologies, Inc., a leading provider of innovative technologies
and services for pharmaceutical development and manufacturing, announced
today that it has signed a Letter of Intent to establish a complementary
commercialization partnership with Protein'eXpert (Grenoble, France).
Protein'eXpert is a Contract Research Organization devoted to recombinant
protein engineering and production for biomedical research applications
focusing on optimization of valuable target or therapeutic proteins. The
agreement stems from the introduction of the firms through the
Lyonbiopole and Invest in France Agency initiatives in the United States.
The agreement provides for the pairing of each company's highly
complementary expertise to better serve the growing biopharmaceutical
development markets and extends the global commercial activities of each
firm, particularly in Europe and the United States. Clients will gain
access to Protein'eXpert's advanced protein engineering, process
development and optimization expertise, with the full realm of cGMP
manufacturing resources for production and Fill/Finish services from phase
I clinical to commercial manufacturing provided by Althea. These
complementary service offerings will allow both companies to reach larger
markets, broaden services for new and challenging products and to better
match early and late stage client requirements for protein projects.
"The partnership with Althea Technologies is a great opportunity for us.
Their very strong position on the US market and their outstanding
production facilities shall perfectly complement our expertise and set of
services based on Recombinant protein engineering, development and small
scale cGMP production," says Dr. Tristan Rousselle, CEO of Protein'eXpert.
"We are very pleased to enter this agreement with Protein'eXpert. Their
highly regarded science and service standards are a wonderful complement
to Althea's manufacturing services. We are confident that this will
strengthen Althea's presence in Europe and provide Althea clients
valuable early stage process development capabilities," stated Dr. Magda
Marquet, President and Co-CEO of Althea Technologies.
"We have been working with Althea Technologies for several months to
develop the optimal solution for its business in France," said Alexandre
Thermet, Vice President of Invest in France Agency -- North America. "The
level of expertise and innovation offered by the Lyonbiopole cluster, in
addition to recent incentives implemented by the French government, led us
to identify Protein'eXpert as an ideal partner for Althea Technologies. We
will continue to work with Althea to ensure that they fully benefit from
the range of advantages France is currently offering companies in their
field."
About Althea Technologies, Inc.
Althea Technologies, a leading San Diego-based pharmaceutical services
firm, provides critical manufacturing services that support researchers
worldwide in their advancement of novel therapies and efforts to apply new
genomic information. Althea's services include cGMP contract manufacturing
of recombinant proteins, DNA-based therapeutics and vaccines, and aseptic
filling. For more information, visit www.altheatech.com.
About Protein'eXpert, SA.
Located in Grenoble (France), Protein'eXpert provides integrated protein
therapeutics and vaccines development contract services. Recognized as a
leading European player in the recombinant protein field, Protein'eXpert
offers early stage development programme including protein engineering,
process development and small scale cGMP manufacturing services. For more
information, visit www.proteinexpert.com.
Contact:
Althea Technologies, Inc.
Alan Moore
Executive Vice President and
Chief Business Officer
(858) 882-0205
Email Contact
Copyright 2008, Market Wire, All rights reserved.
-0-
